Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present

International Journal for Parasitology: Drugs and Drug Resistance

Volumn 2, Issue , 2012, Pages 126-133

  Sibley, Carol Hopkins ^a   Price, Ric N ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Artemisinin; Drug resistance; Malaria; Surveillance

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTESUNATE; CHLOROQUINE; FOLIC ACID ANTAGONIST; MEFLOQUINE; PYRIMETHAMINE PLUS SULFADOXINE;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CAMBODIA; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITE; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 84861463927     PISSN: 22113207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpddr.2012.03.004     Document Type: Review

References (96)

1. Alker A.P., Lim P., Sem R., Shah N.K., Yi P., Bouth D.M., Tsuyuoka R., Maguire J.D., Fandeur T., Ariey F., Wongsrichanalai C., Meshnick S.R. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 2007, 76:641-647.
2. Anderson T.J., Nair S., Nkhoma S., Williams J.T., Imwong M., Yi P., Socheat D., Das D., Chotivanich K., Day N.P., White N.J., Dondorp A.M. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J. Infect. Dis. 2010, 201:1326-1330.
3. Ariey F., Randrianarivelojosia M., Duchemin J.B., Rakotondramarina D., Ouledi A., Robert V., Jambou R., Jahevitra M., Andrianantenaina H., Raharimalala L., Mauclere P. Mapping of a Plasmodium falciparum pfcrt K76T mutation: a useful strategy for controlling chloroquine resistance in Madagascar. J. Infect. Dis. 2002, 185:710-712.
4. Ariey F., Fandeur T., Durand R., Randrianarivelojosia M., Jambou R., Legrand E., Ekala M.T., Bouchier C., Cojean S., Duchemin J.B., Robert V., Le Bras J., Mercereau-Puijalon O. Invasion of Africa by a single pfcrt allele of south east Asian type. Malar. J. 2006, 5:34.
5. Ashley E.A., Stepniewska K., Lindegardh N., Annerberg A., Kham A., Brockman A., Singhasivanon P., White N.J., Nosten F. How much fat is necessary to optimize lumefantrine oral bioavailability?. Trop. Med. Int. Health 2007, 12:195-200.
6. Barnes K.I., Little F., Smith P.J., Evans A., Watkins W.M., White N.J. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 2006, 80:582-596.
7. Barnes K.I., Watkins W.M., White N.J. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008, 24:127-134.
8. Basco L.K. Molecular epidemiology of malaria in Cameroon. XVI. longitudinal surveillance of in vitro pyrimethamine resistance in Plasmodium falciparum. Am. J. Trop. Med. Hyg. 2003, 69:174-178.
9. Basco L.K., Ringwald P. Molecular epidemiology of malaria in Yaounde, Cameroon I. analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am. J. Trop. Med. Hyg. 1998, 58:369-373.
10. Bell D.J., Nyirongo S.K., Mukaka M., Molyneux M.E., Winstanley P.A., Ward S.A. Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin. Pharmacol. Ther. 2011, 89:268-275.
11. Breman J.G., Alilio M.S., Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am. J. Trop. Med. Hyg. 2004, 71:1-15.
12. Campino S., Auburn S., Kivinen K., Zongo I., Ouedraogo J.B., Mangano V., Djimde A., Doumbo O.K., Kiara S.M., Nzila A., Borrmann S., Marsh K., Michon P., Mueller I., Siba P., Jiang H., Su X.Z., Amaratunga C., Socheat D., Fairhurst R.M., Imwong M., Anderson T., Nosten F., White N.J., Gwilliam R., Deloukas P., MacInnis B., Newbold C.I., Rockett K., Clark T.G., Kwiatkowski D.P. Population genetic analysis of Plasmodium falciparum parasites using a customized illumina goldengate genotyping assay. PLoS One 2011, 6:e20251.
13. Carrara V.I., Zwang J., Ashley E.A., Price R.N., Stepniewska K., Barends M., Brockman A., Anderson T., McGready R., Phaiphun L., Proux S., van Vugt M., Hutagalung R., Lwin K.M., Phyo A.P., Preechapornkul P., Imwong M., Pukrittayakamee S., Singhasivanon P., White N.J., Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009, 4:e4551.
14. Certain L.K., Briceno M., Kiara S.M., Nzila A.M., Watkins W.M., Sibley C.H. Characteristics of plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987-2006. J. Infect. Dis. 2008, 197:1743-1751.
15. Charmot G., Amat-Roze J., Rodhain F., Le Bras J., Coulaud J. Geographic approach to the epidemiology of chloroquine-resistance of Plasmodium falciparum in tropical Africa. Ann. Soc. Belg. Med. Trop. 1991, 71:187-197.
16. Cheeseman I.H., Miller B.A., Nair S., Nkhoma S., Tan A., Tan J.C., Al Saai S., Phyo A.P., Moo C.L., Lwin K.M., McGready R., Ashley E., Imwong M., Stepniewska K., Yi P., Dondorp A.M., Mayxay M., Newton P.N., White N.J., Nosten F., Ferdig M.T., Anderson T.J. A major genome region underlying artemisinin resistance in malaria. Science 2012, 336:79-82.
17. Clyde D.F. Observations on monthly pyrimethamine (daraprim) prophylaxis in an east African village. East Afr. Med. J. 1954, 31:41-46.
18. Contacos P.G., Coatney G.R., Lunn J.S., Chin W. Resistance to cycloguanil pamoate (CI-501) by falciparum malaria in west Pakistan. Am. J. Trop. Med. Hyg. 1965, 14:925-926.
19. Cortese J.F., Caraballo A., Contreras C.E., Plowe C.V. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in south America. J. Infect. Dis. 2002, 186:999-1006.
20. Davis R.G., Kamanga A., Castillo-Salgado C., Chime N., Mharakurwa S., Shiff C. Early detection of malaria foci for targeted interventions in endemic southern Zambia. Malar. J. 2011, 10:260.
21. Diourte Y., Djimde A., Doumbo O.K., Sagara I., Coulibaly Y., Dicko A., Diallo M., Diakite M., Cortese J.F., Plowe C.V. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in mali. Am. J. Trop. Med. Hyg. 1999, 60:475-478.
22. Dondorp A.M., Nosten F., Yi P., Das D., Phyo A.P., Tarning J., Lwin K.M., Ariey F., Hanpithakpong W., Lee S.J., Ringwald P., Silamut K., Imwong M., Chotivanich K., Lim P., Herdman T., An S.S., Yeung S., Singhasivanon P., Day N.P.J., Lindegardh N., Socheat D., White N.J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
23. Dondorp A.M., Yeung S., White L., Nguon C., Day N.P.J., Socheat D., von Seidlein L. Artemisinin resistance. current status and scenarios for containment. Nat. Rev. Microbiol. 2010, 8:272-280.
24. Doumbo O.K., Kayentao K., Djimde A., Cortese J.F., Diourte Y., Konare A., Kublin J.G., Plowe C.V. Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J. Infect. Dis. 2000, 182:993-996.
25. Duffy P.E., Mutabingwa T.K. Drug combinations for malaria: time to ACT?. Lancet 2004, 363:3-4.
26. Dzinjalamala F.K., Macheso A., Kublin J.G., Taylor T.E., Barnes K.I., Molyneux M.E., Plowe C.V., Smith P.J. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in malawian children. Antimicrob. Agents Chemother. 2005, 49:3601-3606.
27. EANMAT Monitoring antimalarial drug resistance within national malaria control programmes: the EANMAT experience. Trop. Med. Int. Health 2001, 6:891-898.
28. Eldin de Pecoulas P.E., Abdallah B., Dje M.K., Basco L.K., leBras J., Mazzabraud A. Use of a semi-nested PCR diagnosis test to evaluate antifolate resistance of Plasmodium falciparum isolates. Mol. Cell. Probes 1995, 9:391-397.
29. Elyazar I.R., Hay S.I., Baird J.K. Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv. Parasitol. 2011, 74:41-175.
30. Flegg J.A., Guerin P.J., White N.J., Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar. J. 2011, 10:339.
31. Gething P.W., Patil A.P., Smith D.L., Guerra C.A., Elyazar I.R., Johnston G.L., Tatem A.J., Hay S.I. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar. J. 2011, 10:378.
32. Gething P.W., Van Boeckel T.P., Smith D.L., Guerra C.A., Patil A.P., Snow R.W., Hay S.I. Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax. Parasitol. Vectors 2011, 4:92.
33. Hanpithakpong W., Kamanikom B., Singhasivanon P., White N.J., Day N.P., Lindegardh N. A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. Bioanalysis 2009, 1:37-46.
34. Hastings I.M. A model for the origins and spread of drug-resistant malaria. Parasitology 1997, 115(Pt 2):133-141.
35. Hastings I., Watkins W. Tolerance is the key to understanding antimalarial drug resistance 2006, Trends Parasitol.
36. Hitchings G.H. Nobel lecture in physiology or medicine-1988. selective inhibitors of dihydrofolate reductase. In Vitro Cell. Dev. Biol. 1989, 25:303-310.
37. Hitchings G.S., Burchall J.J. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv. Enzymol. 1965, 27:417-468.
38. Hitchings G.H., Falco E.A., Vanderwerff H., Russell P.B., Elion G.B. Antagonists of nucleic acid derivatives. VII. 2,4-Diaminopyrimidines. J. Biol. Chem. 1952, 199:43-56.
39. Kublin J., Dzinjalamala F., Kamwendo D., Malkin E., Cortese J., Martino L., Mukadam R., Rogerson S., Lescano A., Molyneux M., Winstanley P., Chimpeni P., Taylor T., Plowe C. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis. 2002, 185:380-388.
40. Laufer M., Thesing P., Eddington N., Masonga R., Dzinjalamala F., Takala S., Taylor T., Plowe C. Return of chloroquine antimalarial efficacy in Malawi. N. Engl. J. Med. 2006, 355:1959-1966.
41. Laufer M.K., Djimde A.A., Plowe C.V. Monitoring and deterring drug-resistant malaria in the era of combination therapy. Am. J. Trop. Med. Hyg. 2007, 77:160-169.
42. Lim P., Alker A.P., Khim N., Shah N.K., Incardona S., Doung S., Yi P., Bouth D.M., Bouchier C., Puijalon O.M., Meshnick S.R., Wongsrichanalai C., Fandeur T., Le Bras J., Ringwald P., Ariey F. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 2009, 8:11.
43. Lim, P., Wongsrichanalai, C., Chim, P., Khim, N., KIM, S., Chy, S., Sem, R., Nhem, S., Yi, P., Duong, S., Bouth, D.M., Genton, B., Beck, H.-P., Gobert, J.G., Rogers, W.O., Coppee, J.-Y., Fandeur, T., Mercereau-Puijalon, O., Ringwald, P., Le Bras, J., Ariey, F., 2010. Decreased in vitro susceptibility of Plasmodium falciparum Isolates to artesunate, mefloquine, chloroquine and quinine in Cambodia from 2001 to 2007. Antimicrob. Agents Chemother., AAC.01304-01309.
44. Lindegardh N., Annerberg A., White N.J., Day N.P. Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma stable isotope labeled internal standard does not always compensate for matrix effects. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 862:227-236.
45. Maiga O., Djimde A.A., Hubert V., Renard E., Aubouy A., Kironde F., Nsimba B., Koram K., Doumbo O.K., Bras J.L., Clain J. A shared asian origin of the triple-mutant dhfr allele in Plasmodium falciparum from sites across Africa. J. Infect. Dis. 2007, 196:165-172.
46. Mberu E.K., Mosobo M.K., Nzila A.M., Kokwaro G.O., Sibley C.H., Watkins W.M. The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am. J. Trop. Med. Hyg. 2000, 62:396-401.
47. Mendez F., Munoz A., Carrasquilla G., Jurado D., Arevalo-Herrera M., Cortese J.F., Plowe C.V. Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria. Am. J. Epidemiol. 2002, 156:230-238.
48. Mendez F., Herrera S., Murrain B., Gutierrez A., Moreno L., Manzano M., Munoz A., Plowe C. Selection of antifolate-resistant Plasmodium falciparum by sulfadoxine-pyrimethamine treatment and infectivity to anopheles mosquitoes. Am. J. Trop. Med. Hyg. 2007, 77:438-443.
49. Menemedengue V., Sahnouni K., Basco L., Tahar R. Molecular epidemiology of malaria in Cameroon. XXX. sequence analysis of Plasmodium falciparum ATPase 6, dihydrofolate reductase, and dihydropteroate synthase resistance markers in clinical isolates from children treated with an artesunate-sulfadoxine-pyrimethamine combination. Am. J. Trop. Med. Hyg. 2011, 85:22-25.
50. Mint Lekweiry K., Ould Mohamed Salem Boukhary A., Gaillard T., Wurtz N., Bogreau H., Hafid J.E., Trape J.-F., Bouchiba H., Ould Ahmedou Salem M.S., Pradines B., Rogier C., Basco L.K., Briolant S. Molecular surveillance of drug-resistant Plasmodium vivax using pvdhfr, pvdhps and pvmdr1 markers in nouakchott, mauritania. J. Antimicrob. Chemother. 2012, 67:367-374.
51. Mita T., Venkatesan M., Ohashi J., Culleton R., Takahashi N., Tsukahara T., Ndounga M., Dysoley L., Endo H., Hombhanje F., Ferreira M.U., Plowe C.V., Tanabe K. Limited geographic origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J. Infect. Dis. 2011, 204:1980-1988.
52. Mok S., Imwong M., Mackinnon M.J., Sim J., Ramadoss R., Yi P., Mayxay M., Chotivanich K., Liong K.Y., Russell B., Socheat D., Newton P.N., Day N.P., White N.J., Preiser P.R., Nosten F., Dondorp A.M., Bozdech Z. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 2011, 12:391.
53. Nkhoma S., Molyneux M., Ward S. Molecular surveillance for drug-resistant Plasmodium falciparum malaria in Malawi. Acta Trop. 2007, 102:138-142.
54. Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 2008, 359:2619-2620.
55. Noranate N., Durand R., Tall A., Marrama L., Spiegel A., Sokhna C., Pradines B., Cojean S., Guillotte M., Bischoff E., Ekala M., Bouchier C., Fandeur T., Ariey F., Patarapotikul J., LeBras J., Trape J., Rogier C., Mercereau-Puijalon O. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One 2007, 2:e139.
56. Nosten F., van Vugt M., Price R., Luxemburger C., Thway K.L., Brockman A., McGready R., ter Kuile F., Looareesuwan S., White N.J. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000, 356:297-302.
57. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol. Today 1987, 3:241-246.
58. Pearce R.J., Pota H., Evehe M.S., Ba el H., Mombo-Ngoma G., Malisa A.L., Ord R., Inojosa W., Matondo A., Diallo D.A., Mbacham W., van den Broek I.V., Swarthout T.D., Getachew A., Dejene S., Grobusch M.P., Njie F., Dunyo S., Kweku M., Owusu-Agyei S., Chandramohan D., Bonnet M., Guthmann J.P., Clarke S., Barnes K.I., Streat E., Katokele S.T., Uusiku P., Agboghoroma C.O., Elegba O.Y., Cisse B., IE A.E., Giha H.A., Kachur S.P., Lynch C., Rwakimari J.B., Chanda P., Hawela M., Sharp B., Naidoo I., Roper C. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med. 2009, 6:e1000055.
59. Peters W. The problem of drug resistance in malaria. Parasitology 1985, 90(Pt 4):705-715.
60. Peters W. Chemotherapy and Drug Resistance in Malaria 1987, Academic Press, London. second ed.
61. Peterson D.S., Walliker D., Wellems T.E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA 1988, 85:9114-9118.
62. Phyo A.P., Nkhoma S., Stepniewska K., Ashley E.A., Nair S., McGready R., ler Moo C., Al-Saai S., Dondorp A.M., Lwin K.M., Singhasivanon P., Day N.P.J., White N.J., Anderson T.J.C., Nosten F. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. The Lancet 2012.
63. Picot S., Olliaro P., de Monbrison F., Bienvenu A., Price R., Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 2009, 8:89.
64. Plowe C. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr. Top. Microbiol. Immunol. 2005, 295:55-79.
65. Plowe C.V. Monitoring antimalarial drug resistance. making the most of the tools at hand. J. Exp. Biol. 2003, 206:3745-3752.
66. Plowe C.V. The evolution of drug-resistant malaria. Trans. R. Soc. Trop. Med. Hyg. 2009, 103(Suppl. 1):S11-S14.
67. Plowe C.V., Kublin J.G., Doumbo O.K. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations:epidemiology and role in clinical resistance to antifolates. Drug Resist. Updat. 1998, 1:389-396.
68. Price R.N., Cassar C., Brockman A., Duraisingh M., van Vugt M., White N.J., Nosten F., Krishna S. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 1999, 43:2943-2949.
69. Price R.N., Nosten F. Drug resistant falciparum malaria: clinical consequences and strategies for prevention. Drug Resist. Updat. 2001, 4:187-196.
70. Price R.N., Uhlemann A.C., Brockman A., McGready R., Ashley E., Phaipun L., Patel R., Laing K., Looareesuwan S., White N.J., Nosten F., Krishna S. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
71. Rogers W.O., Sem R., Tero T., Chim P., Lim P., Muth S., Socheat D., Ariey F., Wongsrichanalai C. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar. J. 2009, 8:10.
72. Roper C., Pearce R., Bredenkamp B., Gumede J., Drakeley C., Mosha F., Chandramohan D., Sharp B. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174-1181.
73. Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F., Anderson, T., 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305, 1124-.
74. Sibley C.H., Barnes K.I., Watkins W.M., Plowe C.V. A network to monitor antimalarial drug resistance. a plan for moving forward. Trends Parasitol. 2008, 24:43-48.
75. Sibley C.H., Hyde J.E., Sims P.F.G., Plowe C.V., Kublin J.G., Mberu E.K., Cowman A.F., Winstanley P.A., Watkins W.M., Nzila A.M. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next?. Trends Parasitol. 2001, 17:570-571.
76. Sibley C.H., Guerin P.J., Ringwald P. Monitoring antimalarial resistance. launching a cooperative effort. Trends Parasitol. 2010, 26:221-224.
77. Smith D., Klein E., McKenzie F.E., Laxminarayan R. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar. J. 2010, 9:217.
78. Tatem A.J., Smith D.L. International population movements and regional Plasmodium falciparum malaria elimination strategies. Proc. Natl. Acad. Sci. USA 2010, 107:12222-12227.
79. ter Kuile F.O., Nosten F., Thieren M., Luxemburger C., Edstein M.D., Chongsuphajaisiddhi T., Phaipun L., Webster H.K., White N.J. High-dose mefloquine in the treatment of multidrug-resistant falciparum malaria. J. Infect. Dis. 1992, 166:1393-1400.
80. Triglia T., Cowman A.F. The mechanism of resistance to sulfa drugs in Plasmodium falciparum. Drug Resist. Updat. 1999, 2:15-19.
81. Verret W., Dorsey G., Nosten F., Price R. The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malar. J. 2009, 8:77.
82. Watkins W.M., Sixsmith D.G., Chulay J.D., Spencer H.C. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol. Biochem. Parasitol. 1985, 14:55-61.
83. Wernsdorfer W.H., Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol. Ther. 1991, 50:95-121.
84. White N.J. Antimalarial drug resistance. J. Clin. Invest. 2004, 113:1084-1092.
85. White N.J. Artemisinin resistance-the clock is ticking. Lancet 2010, 376:2051-2052.
86. White N.J. The parasite clearance curve. Malar. J. 2011, 10:278.
87. White N.J., Olliaro P.L. Strategies for the prevention of antimalarial drug resistance. rationale for combination chemotherapy for malaria. Parasitol. Today 1996, 12:399-401.
88. White N.J., Stepniewska K., Barnes K., Price R.N., Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level?. Trends Parasitol. 2008, 24:159-163.
89. WHO Guidelines for the treatment of malaria 2006, WHO, Geneva.
90. WHO Guidelines for Treatment of Malaria 2010, second ed, WHO.
91. WHO Global Plan for Artemisinin Resistance Containment 2011, WHO, Geneva.
92. WHO Methods and Techniques for Assessing Exposure to Antimalarial Drugs in Clinical Field Studies 2011, WHO, Geneva.
93. Wongsrichanalai C., Pickard A.L., Wernsdorfer W.H., Meshnick S.R. Epidemiology of drug-resistant malaria. Lancet Infect. Dis. 2002, 2:209-218.
94. Wootton J.C. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002, 418:320-323.
95. Wu T., Nagle A., Kuhen K., Gagaring K., Borboa R., Francek C., Chen Z., Plouffe D., Goh A., Lakshminarayana S.B., Wu J., Ang H.Q., Zeng P., Kang M.L., Tan W., Tan M., Ye N., Lin X., Caldwell C., Ek J., Skolnik S., Liu F., Wang J., Chang J., Li C., Hollenbeck T., Tuntland T., Isbell J., Fischli C., Brun R., Rottmann M., Dartois V., Keller T., Diagana T., Winzeler E., Glynne R., Tully D.C., Chatterjee A.K. Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J. Med. chem. 2011, 54:5116-5130.
96. Young M.D., Burgess R.W. Pyrimethamine resistance in Plasmodium vivax malaria. Bull. World Health Org. 1959, 20:27-36.